曲美替尼
医学
恶性肿瘤
化疗
癌症研究
药品
肉瘤
肿瘤科
内科学
病理
药理学
生物
激酶
MAPK/ERK通路
细胞生物学
作者
Weifang Wang,Xiuhao Zhao,Ruirong Yi
标识
DOI:10.1016/j.bbrc.2022.07.052
摘要
Epithelioid sarcoma (ES) is a very rare mesenchymal malignancy. Its oncogenesis remains unknown, and few therapies are available for advanced patients. Improved therapies, such as combined therapies, are urgently needed for the treatment of advanced ES. To identify precision drugs for advanced ES patients, the sensitivity of the drugs must be screened and evaluated before they are used for treatment. In the present study, tumour tissue from an ES patient was subjected to NGS sequencing, cell culture and the construction of a PDX model. Using the early generations of tumour-derived cells, we performed a screen and found that the combined drugs ADM and trametinib exhibited coefficiency in tumour inhibition. This conclusion was further confirmed in experiments with later generations of cells and PDX models. Therefore, we suggest that early generations of tumour-derived cells be used to test the sensitivity of ES tumours to candidate drugs. Moreover, we speculate that trametinib may be combined with chemotherapy in ES patients to prolong the duration of the chemotherapeutic response.
科研通智能强力驱动
Strongly Powered by AbleSci AI